437 related articles for article (PubMed ID: 26639968)
1. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
[TBL] [Abstract][Full Text] [Related]
2. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
de Groot M; Aronica E; Heimans JJ; Reijneveld JC
Neurology; 2011 Aug; 77(6):532-9. PubMed ID: 21795655
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Sanchez PE; Zhu L; Verret L; Vossel KA; Orr AG; Cirrito JR; Devidze N; Ho K; Yu GQ; Palop JJ; Mucke L
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2895-903. PubMed ID: 22869752
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer's Disease.
Stockburger C; Eckert S; Eckert GP; Friedland K; Müller WE
J Alzheimers Dis; 2018; 64(s1):S455-S467. PubMed ID: 29504539
[TBL] [Abstract][Full Text] [Related]
5. Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam.
Stockburger C; Kurz C; Koch KA; Eckert SH; Leuner K; Müller WE
Biochem Soc Trans; 2013 Oct; 41(5):1331-4. PubMed ID: 24059528
[TBL] [Abstract][Full Text] [Related]
6. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice.
Devi L; Ohno M
Neurobiol Learn Mem; 2013 May; 102():7-11. PubMed ID: 23416036
[TBL] [Abstract][Full Text] [Related]
7. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
Gillard M; Chatelain P; Fuks B
Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.
Dragicevic N; Mamcarz M; Zhu Y; Buzzeo R; Tan J; Arendash GW; Bradshaw PC
J Alzheimers Dis; 2010; 20 Suppl 2():S535-50. PubMed ID: 20463404
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function.
Stockburger C; Miano D; Pallas T; Friedland K; Müller WE
Neural Plast; 2016; 2016():8075903. PubMed ID: 27747106
[TBL] [Abstract][Full Text] [Related]
11. Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease.
Xiao R
Curr Top Med Chem; 2016; 16(5):565-73. PubMed ID: 26268327
[TBL] [Abstract][Full Text] [Related]
12. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline.
Reddy PH; Manczak M; Mao P; Calkins MJ; Reddy AP; Shirendeb U
J Alzheimers Dis; 2010; 20 Suppl 2(Suppl 2):S499-512. PubMed ID: 20413847
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Dysfunction Triggers Synaptic Deficits via Activation of p38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.
Yu Q; Du F; Douglas JT; Yu H; Yan SS; Yan SF
J Alzheimers Dis; 2017; 59(1):223-239. PubMed ID: 28598851
[TBL] [Abstract][Full Text] [Related]
15. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
Serajee FJ; Huq AM
Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease.
Reddy PH; Manczak M; Yin X; Grady MC; Mitchell A; Kandimalla R; Kuruva CS
J Investig Med; 2016 Dec; 64(8):1220-1234. PubMed ID: 27521081
[TBL] [Abstract][Full Text] [Related]
17. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease.
Calkins MJ; Manczak M; Mao P; Shirendeb U; Reddy PH
Hum Mol Genet; 2011 Dec; 20(23):4515-29. PubMed ID: 21873260
[TBL] [Abstract][Full Text] [Related]
18. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease.
Hall AM; Throesch BT; Buckingham SC; Markwardt SJ; Peng Y; Wang Q; Hoffman DA; Roberson ED
J Neurosci; 2015 Apr; 35(15):6221-30. PubMed ID: 25878292
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.
Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM
PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214
[TBL] [Abstract][Full Text] [Related]
20. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.
Madeo M; Kovács AD; Pearce DA
J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
